Brazil Infectious Disease Therapeutics Market Analysis

Brazil Infectious Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Brazil infectious disease therapeutics market will reach a value of $4.5 Bn from $3.1 Bn in 2022, growing at a CAGR of 5.4% during 2022-2030.

Brazil is an upper middle-income, developing and the largest country in South America bounded by the Atlantic Ocean. Brazil is prone to infectious diseases, according to the World Factbook. Bacterial diarrhoea and hepatitis A are examples of food or waterborne diseases. Dengue fever and malaria are two vector-borne illnesses. In Brazil, water contact disorders include schistosomiasis.

Brazil is also a major producer of vaccines, such as those against yellow fever, measles, and HPV. In Brazil, the Butantan Institute and Fiocruz are two institutes that are actively interested in vaccine development. Brazil's government spends 10.3% of its GDP on healthcare.

Market Dynamics

Market Growth Drivers Analysis

Significant investment has been made in the research and development of infectious disease medicines in Brazil, particularly in the areas of HIV/AIDS, hepatitis C, and tuberculosis. In Brazil, the Brazilian Ministry of Health, the Oswaldo Cruz Foundation (Fiocruz), and a number of research institutions are actively participating in infectious disease therapies research. Several advances in infectious illness therapies have occurred in Brazil in recent years. Brazil, for example, has been a major producer of generic antiretroviral medications for HIV/AIDS, greatly lowering the cost of therapy for those living with the disease. Furthermore, Brazil has made tremendous advances in the discovery of novel tuberculosis medications, such as bedaquiline and delamanid. These aspects could boost Brazil's infectious disease therapeutics market.

Market Restraints

Developing new pharmaceuticals and treatments necessitates adherence to regulatory rules established by organisations such as Brazil's National Health Surveillance Agency (ANVISA). These requirements can be complicated and time-consuming, resulting in delays and higher expenses. In Brazil, infectious diseases such as dengue fever, malaria, and tuberculosis are prevalent. This heavy load can make developing effective therapies and conducting clinical trials difficult. Brazil has high production costs (wages, energy, logistics, and loans) that impact its competitiveness. These factors may deter new entrants into the Brazilian infectious disease therapeutics market.

Competitive Landscape

Key Players

• Fiocruz - Fiocruz is a Brazilian research institution that is involved in the development and production of vaccines, diagnostics, and therapeutics for infectious diseases such as dengue fever, yellow fever, and COVID-19. Fiocruz is also one of the main producers of vaccines for the Brazilian public health system
• Instituto Butantan - Instituto Butantan is a Brazilian research institution that develops and produces vaccines and antivenoms for infectious diseases, including COVID-19. The institute has also been involved in the development of treatments for snake bites, rabies, and other infectious diseases
• Cristália - Cristália is a Brazilian pharmaceutical company that develops and manufactures a range of therapeutics, including antibiotics and antivirals. The company has also been involved in the development of treatments for infectious diseases such as HIV/AIDS and hepatitis B
• Eurofarma - Eurofarma is a Brazilian pharmaceutical company that develops and manufactures a range of generic drugs, including those for infectious diseases such as tuberculosis and malaria
• Aché Laboratórios - Aché Laboratórios is a Brazilian pharmaceutical company that develops and manufactures a range of therapeutics, including antivirals and antibiotics. The company has also been involved in the development of treatments for infectious diseases such as HIV/AIDS and hepatitis B

Recent Notable Updates

November 2022: Eurofarma, a multinational pharmaceutical business established in Brazil and one of the largest in Latin America, announced its debut in the United States market with the acquisition of Medimetriks Pharmaceuticals. Eurofarma's strategic purchase in the United States advances the company's ambition of becoming a worldwide pharmaceutical corporation. This is Eurofarma's first acquisition outside of Latin America, and it comes only weeks after the company was inspected by the United States Food and Drug Administration (FDA), the organisation in charge of drug regulation in the country. 

Healthcare Policies and Reimbursement Scenarios

The Brazilian Health Regulatory Agency (ANVISA) is in charge of the regulation of infectious illness medicines in Brazil. ANVISA is in charge of assessing the safety, efficacy, and quality of all medications and medical equipment, including those used to treat infectious diseases. In order to be approved for use in Brazil, infectious disease treatments must undergo a regulatory process that includes clinical studies and another testing to ensure their safety and efficacy. ANVISA continues to evaluate a product's safety and quality after it has been approved through post-marketing surveillance. In terms of reimbursement, the Brazilian Unified Health System (SUS) gives universal access to healthcare services, including infectious disease treatments.